Wed, Apr 23, 2014, 11:46 AM EDT - U.S. Markets close in 4 hrs 14 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • iounothjing1 iounothjing1 Aug 18, 2012 8:13 AM Flag

    insmed website has changed

    only one job left to be filled.

    insmed has it pipeline listing iplex under other programs.

    http://www.insmed.com/other.php

    IPLEX

    IPLEX is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 (rhIGF-1/rhIGFBP-3) that has been studied as a treatment for several serious medical conditions. We have out-licensed rights to Premacure AB of Sweden to develop, manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3, at lower concentrations than IPLEX for the prevention and treatment of complications of preterm birth. Premacure is currently focusing on retinopathy of prematurity. We also plan to identify licensing partners for other IPLEX development programs.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • mo.farah@rocketmail.com mo.farah Aug 20, 2012 4:39 PM Flag

      Well spotted.
      For what it's worth, you're right. Only Cisplatin was mentioned until recently, iplex, rh-IGFBP3 and insm-18 comments are new.
      cache:http://www.insmed.com/other.php

    • lean forward. Moving in the right direction.

      Good luck.
      Terry

      • 1 Reply to insm_terry
      • you're not kiddin me pal ...

        kvncmcdds 80 cents avg"
        I now own 54,350 shares of insmed once again. "
        ...alone. I could not wait until fall to put my insm profit back to work. On the down...little more now since I have this kind

        of money invested again. Good luck...
        Insmed Incorporated kvnmcddd 3-Aug-11 05:45 pm

        -----------------------
        $17.24 and out of AMLN, will 1,000 bought yesterday and 2,000 bought this morning. Insmed Incorporated kvnmccdd 2-Feb-12 10:28 am

        (INSM was around$4.90

    • "Preclinical models demonstrate that both rhIGFBP-3 and INSM-18 interact with the IGF system to reduce tumor growth. We are not actively pursuing the development of either of these products at this time and have out licensed the rights of INSM-18 to Napo Pharmaceuticals, Inc., for diabetes and to TriAct Therapeutics Inc. for other INSM -18 indications. Due to the high cost of trials in the oncology area, we would need to identify a partner to co-develop rhIGFBP-3."

      Someone is interested in using rhIGFBP-3

      "The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906). The present invention also provides a pharmaceutical composition comprising either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), with a pharmaceutically acceptable carrier."


      http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=619024&mid=619024&tof=56&frt=2

 
INSM
13.89-0.15(-1.07%)11:46 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.